Enapotamab vedotin

Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC) . Enapotamab vedotin also exhibits resistant to EGFR inhibitor such as Osimertinib (HY-15772) [1].

Product Specifications

CAS Number

[1912424-97-5]

Product Name Alternative

HuMax-AXL-ADC

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; TAM Receptor

Related Pathways

Antibody-drug Conjugate/ADC Related; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Enapotamabvedotin]

References & Citations

[1]Koopman LA, et al. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4 (21) :e128199.